320
Participants
Start Date
October 31, 2013
Primary Completion Date
November 30, 2014
Study Completion Date
November 30, 2014
LEO 43204 Formulation 1
LEO 43204 Formulation 2
LEO 43204 Formulation 1 Dose X
LEO 43204 Formulation 1 Dose Y
LEO 43204 Formulation 2 Dose XX
LEO 43204 Formulation 2 Dose YY
Placebo Formulation 1
Placebo Formulation 2
Mount Sinai School of Medicine, New York
DermAssociates, PC, Rockville
Leavitt Medical Associates of Florida, Ormond Beach
Clinical Research Center, Morsani Center for Advanced Healthcare, Tampa
Research Institute of Deaconess Clinic, Evansville
Hudson Dermatology, LLC, Evansville
Henry Ford Medical Center, Dept. of Dermatology, West Bloomfield
Great Lakes Research Group, Inc., Bay City
Clinical Trials of Texas, Inc., San Antonio
Omni Dermatology, Phoenix
Torrance Clinical Research Institute Inc., Lomita
Dermatology Cosmetic Laser Medical Associates of La Jolla, Inc., San Diego
The Dermatology Group, P.C., Verona
Stratica Medical Inc., Edmonton
Guildford Dermatology Specialists, Surrey
Durondel C.P. Inc./Dermatology Clinic, Moncton
Ultranova Skincare, Barrie
Co-Medica Research Network Inc., Courtice
Dermatrials Research Incorporated, Hamilton
The Guenther Dermatology Research Centre, London
Lynderm Research Inc., Markham
SKiN Centre for Dermatology, Peterborough
K. Papp Clinical Research, Waterloo
XLR8 Medical Research, Windsor
Centre de Recherche Dermatologique du Quebec Metropolitain, Québec
Lead Sponsor
LEO Pharma
INDUSTRY